10x Genomics, Inc. Deferred Foreign Income Tax Expense (Benefit)
10x Genomics, Inc. (TXG) reported Deferred Foreign Income Tax Expense (Benefit) of -$310.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-13.
Financial Statements › Expense Statement › Income Tax
us-gaap:DeferredForeignIncomeTaxExpenseBenefit · last filed 2026-02-13
- 10x Genomics, Inc. deferred foreign income tax expense (benefit) for fiscal 2025 was -$310.00K, a 143.72% decline from fiscal 2024.
- 10x Genomics, Inc. deferred foreign income tax expense (benefit) for fiscal 2024 was $709.00K.
- 10x Genomics, Inc. deferred foreign income tax expense (benefit) for fiscal 2023 was -$447.00K, a 428.68% decline from fiscal 2022.
- 10x Genomics, Inc. deferred foreign income tax expense (benefit) for fiscal 2022 was $136.00K.
| Period end | Deferred Foreign Income Tax Expense (Benefit) 12 month |
|---|---|
| 2025-12-31 | -$310.00K 10-K · filed 2026-02-13 |
| 2024-12-31 | $709.00K 10-K · filed 2026-02-13 |
| 2023-12-31 | -$447.00K 10-K · filed 2026-02-13 |
| 2022-12-31 | $136.00K 10-K · filed 2025-02-13 |
| 2021-12-31 | -$690.00K 10-K · filed 2024-02-15 |
| 2020-12-31 | $82.00K 10-K · filed 2023-02-16 |
| 2019-12-31 | -$6.00K 10-K · filed 2022-02-18 |